Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.57 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.57 |
| ▸ | OPRM1 | P35372 | 11/20 | 0.54 |
| ▸ | OPRL1 | P41146 | 11/20 | 0.54 |
| ▸ | OPRK1 | P41145 | 9/20 | 0.54 |
| ▸ | OPRD1 | P41143 | 8/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.51 |
| ▸ | USP2 | O75604 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.50 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.50 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.50 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.50 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.50 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.50 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.50 |
| ▸ | DRD1 | P21728 | 1/20 | 0.50 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2951072 | 0.98 | NPSR1 (0.56) | NPSR1GPR55OPRM1OPRL1OPRK1 | |
| SCHEMBL15464306 | 0.85 | OPRL1 (0.61) | OPRM1OPRL1OPRK1OPRD1CYP3A4 | |
| SCHEMBL10047375 | 0.83 | NPSR1 (0.61) | NPSR1GPR55OPRM1OPRL1OPRK1 | |
| SCHEMBL4016381 | 0.81 | OPRM1 (0.70) | NPSR1GPR55OPRM1OPRL1OPRK1 | |
| SCHEMBL15797515 | 0.80 | NPSR1 (0.57) | NPSR1GPR55OPRM1OPRL1OPRK1 | |
| SCHEMBL28176312 | 0.80 | OPRM1 (0.51) | NPSR1GPR55OPRM1OPRL1OPRK1 | |
| SCHEMBL9359082 | 0.80 | NPSR1 (0.57) | NPSR1GPR55OPRM1OPRL1OPRK1 | |
| SCHEMBL69083 | 0.79 | OPRM1 (0.56) | NPSR1GPR55OPRM1OPRL1OPRK1 | |
| SCHEMBL14742155 | 0.79 | CYP3A4 (0.69) | NPSR1GPR55OPRM1OPRL1OPRK1 | |
| SCHEMBL9358880 | 0.78 | NPSR1 (0.56) | NPSR1GPR55OPRM1OPRL1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 218 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250368666-A1 | INDAZOLE COMPOUNDS | TYRA BIOSCIENCES INC (US) | 2025-12-04 | — | — | US | disclosed |
| EP-4419525-B1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LTD (GB) | 2025-07-23 | — | — | EP | disclosed |
| US-20250230165-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LIMITED (GB) | 2025-07-17 | — | — | US | disclosed |
| EP-4547656-A1 | INDAZOLE COMPOUNDS | Tyra Biosciences, Inc. (US) | 2025-05-07 | — | — | EP | disclosed |
| CN-119731165-A | Indazole compounds | 泰拉生物科学公司 | 2025-03-28 | — | — | CN | disclosed |
| EP-4419525-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | Artios Pharma Limited (GB) | 2024-08-28 | — | — | EP | disclosed |
| CN-118556059-A | Heterocyclic compounds for the treatment of cancer | 阿提奥斯医药有限公司 | 2024-08-27 | — | — | CN | disclosed |
| WO-2024138112-A1 | INDAZOLE COMPOUNDS | TYRA BIOSCIENCES, INC. (US) | 2024-06-27 | — | — | WO | disclosed |
| US-20240132500-A1 | METHOD OF TREATMENT USING SUBSTITUTED PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS | ARRAY BIOPHARMA INC (US) | 2024-04-25 | — | — | US | disclosed |
| WO-2024006897-A1 | INDAZOLE COMPOUNDS | TYRA BIOSCIENCES, INC. (US) | 2024-01-04 | — | — | WO | disclosed |
| US-5410057-A | 1-heteroarylazetidines and -pyrrolidines | SANOFI (FR) | 1995-04-25 | — | — | US | disclosed |
| EP-0406112-B1 | 1-Benzhydrylazetidines, their preparation and their use as intermediates for the preparation of compounds with antimicrobial activity | ESTEVE LABOR DR (ES) | 1994-12-28 | — | — | EP | disclosed |
| EP-0591030-A2 | 1-Heteroaryl-azetidines and -pyrrolidines as 5-HT3 agonists | SANOFI (FR) | 1994-04-06 | — | — | EP | disclosed |
| EP-0529702-A1 | Dihydropyridine derivatives, their preparation and their use | Sankyo Company Limited (JP) | 1993-03-03 | — | — | EP | disclosed |
| CN-1017897-B | DIHYDROPYRIDINE DERIVATIVES, THEIR PREPARATION AND THEIR USE | SANKYO CO (JP) | 1992-08-19 | — | — | CN | disclosed |
| US-5073646-A | Chemical intermediates, microbiocides | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 1991-12-17 | — | — | US | disclosed |
| EP-0406112-A1 | 1-Benzhydrylazetidines, their preparation and their use as intermediates for the preparation of compounds with antimicrobial activity | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 1991-01-02 | — | — | EP | disclosed |
| US-4772596-A | CALCIUM BLOCKERS | SANKYO COMPANY LIMITED (JP) | 1988-09-20 | — | — | US | disclosed |
| EP-0266922-A1 | Dihydropyridine derivatives, their preparation and their use | Sankyo Company Limited (JP) | 1988-05-11 | — | — | EP | disclosed |
| CN-87107150-A | Dihydrogen pyridine derivative and its production and use | — | 1988-05-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240132500-A1 | METHOD OF TREATMENT USING SUBSTITUTED PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS | TYMP, TYMS, P2RX7 | NPSR1 2275/4885GPR55 1448/4885OPRM1 916/4885 |
| US-20250368666-A1 | INDAZOLE COMPOUNDS | FGFR1, FGFR3, FGFR2 | NPSR1 3567/4885GPR55 1167/4885OPRM1 4421/4885 |
| US-20250230165-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | NQO1, VHL, SDHA | NPSR1 3492/4885GPR55 2451/4885OPRM1 1454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.